Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2765 EUR -0.36%
Market Cap: 32m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gensight Biologics SA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Interest Income Expense
€5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Interest Income Expense
-€35.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Interest Income Expense
€2.5m
CAGR 3-Years
N/A
CAGR 5-Years
89%
CAGR 10-Years
31%
G
Genfit SA
PAR:GNFT
Interest Income Expense
-€2.6m
CAGR 3-Years
44%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Interest Income Expense
-€8.2m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Interest Income Expense
-€2.4m
CAGR 3-Years
-51%
CAGR 5-Years
-24%
CAGR 10-Years
-25%
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
32m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.1634 EUR
Overvaluation 41%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Interest Income Expense?
Interest Income Expense
5m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Interest Income Expense amounts to 5m EUR.

What is Gensight Biologics SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-10%

Over the last year, the Interest Income Expense growth was -10%.

Back to Top